Centessa Pharmaceuticals’ Post
More Relevant Posts
-
Today, Centessa shared new preclinical data from non-human primate (NHP) studies of ORX142, an investigational, novel, orexin receptor 2 (OX2R) agonist being advanced for the treatment of excessive daytime sleepiness (EDS) in select neurological, neurodegenerative and psychiatric disorders, at European Sleep Research Society - Sleep Europe 2024. We are focused on rapidly moving ORX142, the second drug candidate from our growing pipeline of OX2R agonists, through IND-enabling studies. #SleepEurope Read full release here: https://lnkd.in/emCdGfQF
To view or add a comment, sign in
-
Thank you Tatiana Corbitt and Katelynn O'Connell for joining our recent Town Hall! In recognition of World Narcolepsy Day, we were honored to host two inspiring patient advocates who shared their personal journeys with narcolepsy. We share their passion to drive awareness for both narcolepsy and other sleep-wake disorders and are committed to helping make a difference. #PatientAdvocacy #WorldNarcolepsyDay #CNTAOX2R
To view or add a comment, sign in
-
September 22nd is World Narcolepsy Day! Join Centessa in raising awareness and understanding about narcolepsy—a chronic sleep disorder that affects millions worldwide. Narcolepsy isn’t just about feeling sleepy; it involves sudden and uncontrollable episodes of falling asleep, cataplexy (sudden loss of muscle tone), and other challenging symptoms. Narcolepsy and other sleep-wake disorders impact daily life. Help shine a light on the experiences of those living with narcolepsy by recognizing World Narcolepsy Day. Together, we can make a difference! Learn more about how the Centessa team is advancing a pipeline of potential best-in-class orexin receptor 2 (OX2R) agonists for the treatment of narcolepsy and idiopathic hypersomnia, as well as excessive daytime sleepiness (EDS) in select neurological, neurodegenerative, and psychiatric disorders. https://lnkd.in/etK4De5m #WorldNarcolepsyDay #NarcolepsyAwareness
To view or add a comment, sign in
-
Based on the positive interim data from the ongoing Phase 1 study reported today, Centessa plans to advance ORX750 into Phase 2 studies in patients with narcolepsy type 1, narcolepsy type 2 and idiopathic hypersomnia, beginning in the fourth quarter of 2024. Centessa plans to further leverage these data to expedite the progression of its multi-asset orexin franchise to potentially treat excessive daytime sleepiness across multiple disorders. Read more here: https://lnkd.in/eyW74rkC
To view or add a comment, sign in
-
Today, Centessa announced positive interim data from the ongoing Phase 1 study of ORX750, a potential best-in-class oral OX2R agonist for the treatment of sleep-wake disorders. At a 2.5 mg once-daily dose, ORX750 was shown to restore normative wakefulness in acutely sleep-deprived healthy volunteers and, as of the data cutoff date, has demonstrated a favorable safety and tolerability profile. To learn more, click here: https://lnkd.in/eyW74rkC
To view or add a comment, sign in
-
Centessa is thrilled to announce that non-human primate preclinical data for our newest orexin development candidate will be featured in a late-breaking poster presentation at the upcoming European Sleep Research Society Sleep Europe 2024 meeting on September 26, 2024. See the release for more details: https://lnkd.in/eMTMzeSZ
To view or add a comment, sign in
-
Today, Centessa announced that members of our management team will participate in the Morgan Stanley 22nd Annual Global Healthcare Conference on Wednesday, September 4, 2024.
To view or add a comment, sign in
-
We were thrilled to host Dr. Emmanuel JM Mignot, a renowned sleep expert and member of our Scientific Advisory Board, for an engaging discussion on advancements in sleep research at our recent Town Hall. Dr. Mignot, recognized for discovering the cause of narcolepsy as the loss of orexin-producing neurons in the brain, shared his groundbreaking insights into the science of sleep and its impact on overall health, offering us a deeper understanding of patient challenges with existing treatments. A huge thank you to Dr. Mignot for sharing his expertise, and to everyone who joined us for this incredible event. At Centessa, we’re energized and inspired to continue exploring the science of sleep for the benefit of those living with sleep-wake disorders. #SleepMedicine #DrEmmanuelMignot
To view or add a comment, sign in
-
Today, we announced financial results and business highlights for the second quarter of 2024. Read the full press release for more details: https://lnkd.in/eG5gy4Jx
To view or add a comment, sign in
6,686 followers